142nd APHA Annual Meeting and Exposition

Annual Meeting Recordings are now available for purchase

307947
How one central cancer registry (CCR) navigated EHR reporting from Clinic/Physician Offices (C/POs)

142nd APHA Annual Meeting and Exposition (November 15 - November 19, 2014): http://www.apha.org/events-and-meetings/annual
Wednesday, November 19, 2014 : 10:30 AM - 10:50 AM

Jeannette Jackson-Thompson, MSPH, PhD , MU Informatics Institute, University of Missouri, Columbia, MO
Chester Schmaltz, PhD , Missouri Cancer Registry and Research Center/Dept. of Health Management & Informatics, University of Missouri--Columbia, School of Medicine, Columbia, MO
BACKGROUND: In 2010, the Missouri Cancer Registry and Research Center (MCR-ARC) received American Recovery and Reinvestment Act (ARRA) funding from the Centers for Disease Control and Prevention (CDC) National Program of Cancer Registries (NPCR) through a subcontract with Macro International to demonstrate receipt and processing of electronic health records (EHRs) from C/POs. While all states have laws or statutes mandating the reporting of non-hospital as well as hospital-based cancer cases, many of the 45 states (plus the District of Columbia) funded by CDC’s NPCR have had difficulty obtaining cases diagnosed and treated in a C/PO due to staffing and funding issues for both CCRs and C/POs. With some types of cancer (e.g., melanoma skin cancer, prostate cancer, leukemia, lymphoma, in situ and localized breast cancer, etc.) increasingly being diagnosed and treated outside a hospital setting, failure to capture these cases has a negative impact on the completeness of cancer incidence data. Where you live may affect your health and well-being but if complete, timely and accurate data are not available, public health officials and other decision-makers may not know it. Implementation of Stage 2 Meaningful Use – Cancer Reporting offered an opportunity to obtain needed data.

PURPOSE: Describe steps the CCR took to facilitate receipt and processing of EHR records formatted for cancer reporting using Clinical Document Architecture (CDA) from certified Meaningful Use (MU) Stage 2 EHR vendors.

METHODS: We identified pilot sites and obtained written confirmation of participation. We worked with each site's EHR vendor to facilitate receipt of complete cancer case reporting. We requested a test file from each site. Initial test files were submitted in a non-CDA format. We sent test files to CDC for review. Vendors made changes as needed. In early 2013, we began receiving test files in the CDA format required for compliance with MU Stage 2 and repeated the review process.

RESULTS: Guidelines and procedures were created to facilitate onboarding of additional C/POs by the state health department. These procedures, adopted into the department’s and CCR’s operations, will be demonstrated.

DISCUSSION: Procedures developed to facilitate EHR reporting to one CCR can be used by other CCRs to increase C/PO reporting. These procedures make for an easier transition of CDA files to abstracts used in cancer reporting. This allows the CCR to improve completeness. How health is affected by where patients live can be assessed and disparities addressed.

Learning Areas:

Clinical medicine applied in public health
Communication and informatics
Other professions or practice related to public health
Public health or related laws, regulations, standards, or guidelines
Public health or related organizational policy, standards, or other guidelines
Public health or related research

Learning Objectives:
Discuss the procedures implemented for EHR reporting from C/POs to a CCR. Identify at least two barriers for clinicians and public health entities in implementing EHR reporting. Demonstrate success of CCR and health department in structuring standard cancer reporting from EHRs.

Keyword(s): Information Technology, Data Collection and Surveillance

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I am the Director of the Missouri Cancer Registry and Research Center and Principal Investigator for the project described here. I am responsible for the work being presented.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.